Target Information

AorticLab, established in 2017, is a pioneering startup focused on innovating and enhancing treatment methods for patients suffering from aortic valve stenosis. The company recently completed a capital increase of €1.3 million, primarily funded by investors from the Doorway platform, members of the Italian Angels for Growth (IAG), and the Investors' Club. This influx of capital enables AorticLab to further advance its promising projects in the development pipeline.

Among the investors in this capital raise were prominent industry stakeholders and angel investors who previously contributed over €800,000 in May. This investment supports the completion of a

View Source

Similar Deals

CDP Venture Capital Arsenale Bioyards

2025

Seed Stage Biotechnology & Medical Research (NEC) Italy
Utopia SIS PerFormS Srl

2023

Seed Stage Proprietary & Advanced Pharmaceuticals Italy
Claris Ventures ALKemist Bio

2023

Seed Stage Bio Therapeutic Drugs Italy
Utopia SIS and Pariter Partners LighthouseBiotech

2023

Seed Stage Biotechnology & Medical Research (NEC) Italy
IAG and Doorway Rejoint

2023

Seed Stage Medical Prosthetics Italy
a|impact AmaliaCare

2023

Seed Stage Home Healthcare Services Italy

Italian Angels for Growth, Club degli Investitori, Doorway

invested in

AorticLab

in 2023

in a Seed Stage deal

Disclosed details

Transaction Size: $1M

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert